propranolol accord 40 mg film - coated tablets
accord healtcare ltd. - Пропранолол - 40 mg film - coated tablets
propranolol accord 80 mg film - coated tablets
accord healtcare ltd. - Пропранолол - 80 mg film - coated tablets
ondansetron accord 2 mg/ml solutiotion for injection or infusion
accord healtcare limited, uk - Ондансетрон - 2 mg/ml solutiotion for injection or infusion
telmotens 40 mg film - coated tablets
accord healtcare ltd. - Ранитидин - 40 mg film - coated tablets
ranitidine accord 300 mg film - coated tablets
accord healtcare ltd. - Ранитидин - 300 mg film - coated tablets
simvastatin accord 10 mg film - coated tablets
accord healtcare limited, uk - Симвастатин - 10 mg film - coated tablets
simvastatin accord 20 mg film - coated tablets
accord healtcare limited, uk - Симвастатин - 20 mg film - coated tablets
simvastatin accord 40 mg film - coated tablets
accord healtcare limited, uk - Симвастатин - 40 mg film - coated tablets
entyvio
takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - Селективни имуносупресори - colitisentyvio улцерозен е показан за лечение на възрастни пациенти с вмеру до строго активен язвенному колиту, които са имали недостатъчен отговор, загубил отговор, или с непоносимост или традиционна терапия или некротизиращ алфа (Фноа) антагонист. diseaseentyvio на крон е показан за лечение на възрастни пациенти с болест на Крон, ревматоиден, които са имали недостатъчен отговор, загубил отговор, или с непоносимост или традиционна терапия или некротизиращ алфа (Фноа) антагонист. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.
firmagon
ferring pharmaceuticals a/s - дегареликс - Простатни неоплазми - Ендокринна терапия - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.